Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Post by FredTheVoiceon Apr 01, 2019 5:18pm

161 Views

Post# 29566288

What to think about that ?

Some analysts are sharing their opinion on the news: WHAT DO YOU THINK ABOUT THEIR OPINION ? What does 2023 mean here for the potential ?

"Dewey Steadman of Canaccord Genuity and Endri Leno of National Bank Financial doubt that the company is investing to commercialize a second treatment as it loses the exclusivity patent as early as 2023"

THANKS

FTV.

Bullboard Posts

Changing Europe’s dependency on HREE from China